Silexion Therapeutics Corp is offering 2,028,619 ordinary shares. It filed a Form S-1 registration statement for an initial public offering on September 10, 2024. As of November 6, 2026, its final prospectus is on file (Form 424B4, August 13, 2026).
Who owns Silexion Therapeutics Corp?
Sell to companies like Silexion Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Silexion Therapeutics Corp filed a Form S-1 registration statement for an initial public offering on 2024-09-10. It has amended it 4 times. It filed its final prospectus on 2026-08-13. Each fact below is quoted from the filing named with it.
Also on the record for Silexion Therapeutics Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 28, 2026 | Stake report, Schedule 13D/A, by Moringa Sponsor, LP | 17.7% of the class | 5%+ stakes | Source |
| August 19, 2026 | Stake report, Schedule 13D/A, by Moringa Sponsor, LP | 25% of the class | 5%+ stakes | Source |
| August 18, 2026 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | — | 5%+ stakes | Source |
| July 31, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 23, 2026 | Stake report, Schedule 13D/A, by Moringa Sponsor, LP | 10.6% of the class | 5%+ stakes | Source |
| May 29, 2026 | Stake report, Schedule 13D/A, by Moringa Sponsor, LP | 32.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Lind Global Fund III LP | 4.96% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Lind Global Fund III LP | 6.4% of the class | 5%+ stakes | Source |
| September 23, 2025 | Stake report, Schedule 13D/A, by Moringa Sponsor, LP | 14.67% of the class | 5%+ stakes | Source |
| September 18, 2025 | Stake report, Schedule 13G, by Lind Global Fund III LP | 9.9% of the class | 5%+ stakes | Source |
Check before you invest in Silexion Therapeutics Corp: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Silexion Therapeutics Corp and the records around it.
Silexion Therapeutics Corp elsewhere on the record
- 5%+ stake filings Sep 2026
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
Watch Silexion Therapeutics Corp
Get an email when Silexion Therapeutics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Silexion Therapeutics Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Silexion Therapeutics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Silexion Therapeutics Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
26 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
What the filings say
Shares offered
We are offering 2,028,619 ordinary shares (the “shares”), par value $0.135 per share of Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion”, the “Company”, “our company”, “we” or “us”), together with 3,846,161 ordinary warrants (the “ordinary warrants”), to purchase 3,846,161 ordinary shares at the public offering price of $0.65 per share and ordinary warrant pursuant to this prospectus.From the 424B4 filed 2026-08-13
Use of proceeds
We currently intend to use the net proceeds from this offering to advance our pre-clinical and clinical studies, and for general corporate purposes.From the 424B4 filed 2026-08-13
Net loss or income
We have incurred net losses since our inception in November 2008, including net losses of $2.7 million and $1.7 million for the three months ended March 31, 2026 and 2025, respectively, and $11.9 million for the year ended December 31, 2025.From the S-1/A filed 2026-08-10
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-09-10 | Registration statement filed | S-1 |
| 2024-10-09 | Registration statement filed | S-1 |
| 2024-10-31 | Registration statement filed | S-1 |
| 2025-01-14 | Registration statement amended | S-1/A |
| 2025-01-14 | Registration statement amended | S-1/A |
| 2025-01-17 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-02-12 | Registration statement filed | S-1 |
| 2025-03-27 | Registration statement amended | S-1/A |
| 2025-08-26 | Registration statement filed | S-1 |
| 2025-09-05 | Registration statement filed | S-1 |
| 2025-09-12 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-08-07 | Registration statement filed | S-1 |
| 2026-08-10 | Registration statement amended | S-1/A |
| 2026-08-13 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Silexion Therapeutics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.